Vivace Therapeutics Secures $35 Million in Series D Funding
In a significant development for cancer therapy, Vivace Therapeutics, Inc. recently announced the successful closure of a $35 million Series D financing round. This funding initiative was primarily led by RA Capital Management, with a contribution from existing investors such as Canaan Partners and Cenova Capital. The proceeds from this financing will be utilized to propel the clinical advancement of their first-in-class drug, VT3989, which targets the Hippo pathway and aims to support patients suffering from mesothelioma.
Understanding VT3989: A Game Changer in Cancer Treatment
VT3989 stands as a groundbreaking small molecule therapeutic specifically designed to inhibit palmitoylation within members of the TEAD protein family. This mechanism is critical because it affects how cancer cells proliferate. With over 150 patients currently participating in an ongoing Phase 1 clinical study, VT3989 is the only TEAD autopalmitoylation inhibitor that has demonstrated statistically significant clinical efficacy thus far. Furthermore, the initial findings reveal promising safety profiles, placing this compound in a favorable position to redefine cancer therapy norms.
Clinical Progress and Future Trials
The clinical results gathered from the Phase 1 trial have been particularly compelling in patients with mesothelioma who have proven resistant to traditional treatments such as chemotherapy and immuno-oncology therapies. As these results prepare to be showcased at a prominent medical conference in the latter part of 2025, Vivace is actively preparing to transition VT3989 into a randomized registrational Phase 3 trial, aiming for FDA discussions regarding its next steps.
Leadership Insights on Series D Financing
Dr. Jake Simson, a partner at RA Capital Management, articulated the enthusiasm surrounding Vivace's progress since their initial investment during the Series C round. He expressed confidence in the company's trajectory and highlighted their determination to address the unmet needs of mesothelioma patients. Dr. Simson emphasized the importance of VT3989, stating that it has the potential to significantly enhance the standard of care for this challenging disease.
CEO Statement on Future Directions
Expressing optimism, Sofie Qiao, Ph.D., president and CEO of Vivace Therapeutics, commented on the essential next steps for VT3989, indicating their commitment to moving forward with the Phase 3 trial. She conveyed gratitude towards RA Capital, Canaan Partners, and Cenova Capital for their unwavering support, mentioning that this funding is critical for the progression of VT3989's development in tackling a critical treatment gap in the cancer landscape.
About the Phase 1 Study of VT3989
The Phase 1 study is a multi-center, open-label trial focused on assessing VT3989's safety, tolerability, pharmacokinetics, and biological activity in patients with refractory metastatic solid tumors, which includes those battling pleural malignant mesothelioma. The gathering of clinical data thus far reinforces the potential for future advancements in cancer treatment.
About Vivace Therapeutics, Inc.
Vivace Therapeutics is a pioneering organization dedicated to the discovery and development of small molecule drugs that target the Hippo pathway, a critical area in cancer therapy. With a robust commitment to addressing high unmet medical needs in oncology, Vivace has successfully raised $105 million to date. Their vision includes a focus on innovative cancer drug therapies that could significantly improve the quality of treatment options available to patients.
Frequently Asked Questions
What is VT3989?
VT3989 is an innovative cancer drug developed by Vivace Therapeutics that targets the Hippo pathway and inhibits palmitoylation within the TEAD protein family.
How much funding did Vivace Therapeutics raise?
Vivace Therapeutics recently secured $35 million in Series D financing primarily aimed at advancing the clinical development of VT3989.
What type of cancer is VT3989 being developed to treat?
VT3989 is being developed to treat patients with mesothelioma, particularly those who have not benefitted from existing therapies.
Who led the Series D financing round?
The Series D financing round was led by RA Capital Management, with participation from existing investors including Canaan Partners and Cenova Capital.
What are the next steps for Vivace Therapeutics?
Vivace Therapeutics plans to advance VT3989 into a randomized registrational Phase 3 clinical trial and will engage with the FDA to align on the next steps for the drug's development.
